NuVim Holdings, Inc. is a development-stage biopharmaceutical company focused on creating novel small-molecule therapies for neurodegenerative and neuroinflammatory disorders. Utilizing a proprietary platform of sigma-1 receptor agonists, NuVim is advancing a pipeline of orally available compounds designed to modulate cellular stress pathways and promote neuronal health. Its lead programs target conditions such as Alzheimer’s disease, traumatic brain injury, and other central nervous system indications that currently have limited treatment options.
Leveraging decades of academic research and industry collaboration, NuVim has generated multiple preclinical candidates exhibiting favorable safety and pharmacokinetic profiles. The company’s research and development efforts are supported by integrated chemistry, pharmacology and toxicology capabilities located at its U.S. facilities. In addition to its internal pipeline, NuVim engages in strategic partnerships with contract research organizations and academic institutions to accelerate candidate selection and IND-enabling studies.
Founded in 2010 and incorporated in Delaware, NuVim conducts its clinical planning and corporate operations from headquarters in the United States, with a satellite office in Europe to facilitate regulatory interactions and potential trial sites. The company’s growth strategy includes expanding its pipeline through in-licensing opportunities, advancing lead compounds toward human proof-of-concept studies, and exploring collaborative alliances for commercialization.
NuVim is led by an experienced management team with extensive backgrounds in biopharmaceutical development, regulatory affairs and business strategy. Under the guidance of its executive leadership and scientific advisory board, the company remains focused on translating its sigma-1 receptor platform into first-in-class treatments that address significant unmet needs in neurodegeneration and brain injury.
AI Generated. May Contain Errors.
